Research has been designated as one the four pillars in the Government’s response to the COVID-19 pandemic. Research at Guy’s and St Thomas’ and our Biomedical Research Centre (BRC) is at the heart of the national effort to develop diagnostics and treatments for COVID-19.

The Trust has been participating in a large number of Urgent Public Health Studies approved by the Chief Medical Officer (CMO) such as the platform trials REMAP-CAP and RECOVERY. Through our BRC we are participating in the early phase platform studies, ACCORD and TACTIC.

Our research would not be possible without the help of our research participants. Since the start of the pandemic over 4,200 participants have taken part in the Urgent Public Health Studies and in our local COVID-19 research studies. We are extremely grateful to everyone who has participated in any of our research studies.

On average it has only taken is 13 days to set up the Urgent Public Health studies in the Trust, this has allowed our Principal Investigators and research teams to focus on delivering these important studies and resulted in outstanding performance both globally and nationally. These achievements have been captured through our first COVID-19 research infographic which demonstrates the totality of our contribution to date in delivering the Urgent Public Health and our local COVID-19 studies. The infographic, which also highlights key examples of research outcomes for COVID-19, can be viewed here.

Speaking about our work throughout the pandemic Professor Charles Wolfe, Director of Research and Development at Guy’s and St Thomas’ said: “We are extremely grateful for the dedication and commitment of our research staff and teams across the Trust and within our NIHR Biomedical Research Centre who have played a key role in the response to the COVID-19 pandemic, from being redeployed the front line to deliver vital clinical care to developing and delivering priority COVID-19 research.”

Professor Matt Brown Director of our NIHR Biomedical Research Centre added: “The performance of our research staff and teams in developing and delivering COVID-19 research has been impressive. We are extremely grateful to all the research participants who have enabled us to deliver this COVID-19 research portfolio so rapidly and successfully.”

 

Share: